Silvia Carloni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7969301/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?. British Journal of Haematology, 2020, 189, 335-338.	2.5	6
2	Kevetrin induces apoptosis in TP53 wild‑type and mutant acute myeloid leukemia cells. Oncology Reports, 2020, 44, 1561-1573.	2.6	4
3	Pentoxifylline-Induced Apoptosis in Chronic Lymphocytic Leukemia: New Insights into Molecular Mechanism. Mini-Reviews in Medicinal Chemistry, 2018, 18, 287-294.	2.4	8
4	Unexpected Low Expression of Platelet Fibrinogen Receptor in Patients with Chronic Myeloproliferative Neoplasms: How Does It Change with Aspirin?. Blood, 2018, 132, 1794-1794.	1.4	0
5	The emerging role of GSKâ€3β in the pathobiology of classical Hodgkin lymphoma. Histopathology, 2017, 71, 72-80.	2.9	7
6	Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs. Nature Communications, 2017, 8, 1801.	12.8	36
7	DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy. OncoTargets and Therapy, 2017, Volume 10, 4657-4664.	2.0	3
8	Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial. Oncotarget, 2016, 7, 10193-10202.	1.8	15
9	Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. Oncotarget, 2016, 7, 18424-18439.	1.8	45
10	IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia. Journal of Translational Medicine, 2015, 13, 229.	4.4	23
11	Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report. Annals of Hematology, 2015, 94, 1597-1598.	1.8	2
12	Albumin nanocapsules containing fenretinide: pre-clinical evaluation of cytotoxic activity in experimental models of human non-small cell lung cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 263-273.	3.3	23
13	Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colon rectal cancer: Results from the ITACa trial Journal of Clinical Oncology, 2015, 33, 617-617.	1.6	1
14	Efficacy of Different Sequences of Radio―and Chemotherapy in Experimental Models of Human Melanoma. Journal of Cellular Physiology, 2014, 229, 1548-1556.	4.1	8
15	A New Avenue toward Androgen Receptor Pan-antagonists: C2 Sterically Hindered Substitution of Hydroxy-propanamides. Journal of Medicinal Chemistry, 2014, 57, 7263-7279.	6.4	53
16	Targeting Lon Protease Activity Promotes Growth Inhibition and Apoptosis in Acute Myeloid Leukemia Cell Lines. Blood, 2014, 124, 5130-5130.	1.4	0
17	SLUG silencing increases radiosensitivity of melanoma cells in vitro. Cellular Oncology (Dordrecht), 2013, 36, 131-139.	4.4	18
18	Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease. BMC Cancer, 2013, 13, 542.	2.6	17

SILVIA CARLONI

#	Article	IF	CITATIONS
19	Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Letters, 2013, 335, 225-231.	7.2	208
20	Acute Oxaliplatin-Induced Thrombotic Thrombocytopenic Purpura: A Case Report and Results From a Cytoflourimetric Assay of Platelet Fibrinogen Receptor. Journal of Clinical Oncology, 2013, 31, 2061-2062.	1.6	8
21	Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients. Blood, 2013, 122, 2289-2289.	1.4	0
22	Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell International, 2012, 12, 48.	4.1	19
23	Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. Tumori, 2012, 98, 696-701.	1.1	17
24	Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity. Journal of Cellular Physiology, 2012, 227, 3389-3396.	4.1	24
25	Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. Tumori, 2012, 98, 696-701.	1.1	6
26	Activity of different anthracycline formulations in hormoneâ€refractory prostate cancer cell lines: Role of golgi apparatus. Journal of Cellular Physiology, 2011, 226, 3035-3042.	4.1	7
27	Abstract 4901: Preliminary investigation of circulating NSCLC cells using dielectrophoresis-based instrumentation. , 2011, , .		0
28	Docetaxel–ST1481 sequence exerts a potent cytotoxic activity on hormoneâ€resistant prostate cancer cells by reducing drug resistanceâ€related gene expression. Prostate, 2010, 70, 219-227.	2.3	10
29	Role of RAF/MEK/ERK pathway, pâ€STATâ€3 and Mclâ€1 in sorafenib activity in human pancreatic cancer cell lines. Journal of Cellular Physiology, 2009, 220, 214-221.	4.1	69
30	Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines. Anti-Cancer Drugs, 2009, 20, 918-925.	1.4	12
31	Mitotic catastrophe and apoptosis induced by docetaxel in hormoneâ€refractory prostate cancer cells. Journal of Cellular Physiology, 2008, 217, 494-501.	4.1	51
32	Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. Journal of Translational Medicine, 2008, 6, 43.	4.4	24
33	Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric study. BMC Cell Biology, 2006, 7, 6.	3.0	60